On Thursday, Qiagen got an upgrade to its Relative Strength (RS) Rating, from 64 to 71.
Can You Really Time The Stock Market?
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains typically have an 80 or higher RS Rating in the early stages of their moves. See if Qiagen can continue to show renewed price strength and clear that threshold.
Qiagen is building a cup without handle with a 49.30 buy point. See if it can break out in volume at least 40% above average.
Earnings grew 17% last quarter, up from 7% in the prior report. Revenue also increased, from 2% to 5%.
The company holds the No. 17 rank among its peers in the Medical-Products industry group. Boston Scientific, Insulet and LifeMD are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
